Business
Collaboration with AdventHealth for two studies
CelLBxHealth plc has announced a collaboration with AdventHealth, a large US health system, to utilize its Parsortix platform in two clinical studies, ACTION and SUNRISE, focusing on colon, gastrointestinal, and lung cancers. These multi-centre studies will involve 219 patients in ACTION and 120 patients in SUNRISE, employing circulating tumour cell (CTC) analysis as a correlative endpoint to monitor treatment response and tumour biology non-invasively. This partnership aims to validate and expand the adoption of CelLBxHealth's liquid biopsy technology within a significant healthcare network, potentially improving patient-centric care and addressing health inequalities by bringing advanced cancer monitoring closer to patients. Disclaimer*
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n\n\n \nCelLBxHealth plc\n (\"CelLBxHealth\" or \"the Company\")\n \nCollaboration with AdventHealth for two studies monitoring CTCs to improve cancer care\n \n· AdventHealth, one of the largest faith-based health systems in the United States\n· CTC analysis will be an endpoint in two multi-centre studies in colon, gastrointestinal and lung cancer\n \nGuildford, UK and Plymouth Meeting, U.S. - 18 May 2026 - CelLBxHealth plc (AIM:CLBX), a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces a collaboration with AdventHealth, one of the largest faith-based health systems in the United States, for the use of CelLBxHealth's Parsortix® platform in two clinical studies. The studies, titled ACTION and SUNRISE, will employ minimally invasive cancer monitoring by isolating and analysing circulating tumour cells (CTCs) from patients undergoing treatment.\n \nThese studies mark an important advance in the use of minimally invasive diagnostics to better understand treatment response, improve outcomes, and expand access to precision oncology in community settings. Using the Parsortix platform, researchers will isolate and analyse CTCs from blood samples, enabling both enumeration and PD-L1 characterisation to provide real-time insight into tumour biology without the need for invasive biopsies.\n \nThe ACTION study (Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer) is a multi-site, NIH-funded trial currently enrolling 219 patients to evaluate how different doses of aerobic exercise influence chemotherapy tolerability in colon cancer patients (NCT05773144). The SUNRISE study (Statewide Unified Network for Remote Intervention of Strength and Exercise) is a digitally enabled trial in 120 patients with gastrointestinal and lung cancers, assessing whether remotely delivered exercise interventions can improve chemotherapy tolerance and quality of life expected to commence in July 2026. Across both studies, CTC analysis will serve as a novel correlative endpoint, helping researchers understand how the tumour evolves in response to treatment and behavioural interventions.\n \nA central aim of both studies is to enable more pat...